

CITATION REPORT

List of articles citing

Drug interactions with amiodarone

DOI: 10.1016/0002-8703(83)90017-0
American Heart Journal, 1983, 106, 924-30.

Source: <https://exaly.com/paper-pdf/16389614/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
126	Cardiovascular Effects of Drug Interactions between Anesthetics and Cardiovascular Medications. 1986 , 1, 224-259		
125	Possible interaction between amiodarone and phenytoin. 1984 , 101, 650-1		27
124	The electrophysiology and pharmacology of verapamil, flecainide, and amiodarone: correlations with clinical effects and antiarrhythmic actions. 1984 , 432, 210-35		7
123	Clinical pharmacology of amiodarone. 1984 , 427, 112-26		5
122	Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. 1984 , 4, 111-6		96
121	Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects. 1984 , 3, 1059-71		194
120	Clinical pharmacokinetics of the newer antiarrhythmic agents. 1984 , 9, 375-403		45
119	Subcostal M-mode echocardiography of atrial septum for diagnosis of atrial flutter. 1984 , 54, 1143-5		5
118	Interaction of amiodarone and diphenylhydantoin. 1984 , 54, 1145		24
117	Clinical pharmacokinetics of amiodarone. 1984 , 9, 136-56		218
116	Potential of the action of oral anticoagulants by amiodarone. 1984 , 39, 306-8		
115	Clinical use and pharmacology of amiodarone. 1984 , 68, 1339-66		31
114	Antiarrhythmic therapy: clinical pharmacology update. 1984 , 24, 295-305		2
113	Cardiac glycosides and drugs used in dysrhythmias. 1985 , 9, 158-170		
112	Mechanism of warfarin potentiation by amiodarone: dose--and concentration--dependent inhibition of warfarin elimination. 1985 , 28, 257-61		62
111	Propafenone. 1985 , 3, 285-299		
110	Tissue-serum correlates of digoxin-amiodarone pharmacokinetic interaction in rats: evidence for selective tissue accumulation and reduced tissue binding. 1985 , 74, 1067-70		6

109	Antiarrhythmic drug therapy (Part 2). Benefits and hazards. 1985 , 88, 618-24	10
108	Amiodarone: pharmacology and antiarrhythmic and adverse effects. 1985 , 5, 298-313	44
107	Amiodarone reduces plasma warfarin clearance in man. 1985 , 20, 707-9	20
106	Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. 1985 , 6, 1402-7	142
105	Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. 1986 , 57, 25B-33B	42
104	Formation of an inactive cytochrome P-450Fe(II)-metabolite complex after administration of amiodarone in rats, mice and hamsters. 1986 , 35, 2213-20	29
103	Flecainide and amiodarone interaction. 1986 , 7, 1127-30	55
102	Polarisation de fluorescence. 1986 , 1, 33-35	
101	Amiodarone in Pediatric Patients. 1986 , 4, 522-527	3
100	The Efficacy of Propafenone for Treatment of Ventricular Ectopic Depolarizations. 1986 , 4, 528-534	1
99	Amiodarone-Induced Thrombocytopenia. 1987 , 147, 735	14
98	Clinical value of plasma concentrations of antiarrhythmic drugs. 1987 , 8 Suppl A, 83-9	19
97	Class III drugs: amiodarone. 1987 , 8 Suppl A, 53-9	5
96	Newer antiarrhythmic drugs in children. <i>American Heart Journal</i> , 1987 , 113, 179-85	4-9 27
95	Amiodarone. 1987 , 316, 455-66	430
94	Wechselwirkungen zwischen Beta- Rezeptorenblockern und Antiarrhythmika. 1987 , 255-272	7
93	Cardiovascular Drugs in Pregnancy. 1987 , 5, 651-674	20
92	Neurological complications of cardiovascular therapy. 1987 , 12, 153-211	5

91	Part III: Class IC Antiarrhythmic Drugs A Review of Their Pharmacokinetics, Electrophysiology, Efficacy, and Toxicity*. 1987 , 1, 435-465	2
90	Effect of amiodarone and desethylamiodarone on the pharmacokinetics of antipyrine in the rat. 1987 , 4, 251-4	5
89	Effect of amiodarone on the disposition of procainamide in the rat. 1988 , 77, 662-5	9
88	Initial dosage selection of antiarrhythmic therapy. 1988 , 62, 2H-8H	2
87	Chronic ventricular arrhythmias: which drug for which patient?. 1988 , 61, 83A-94A	1
86	Combination therapy for cardiac arrhythmias. 1988 , 61, 95A-101A	22
85	Discussion. 1988 , 61, A100-A101	
84	Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol. <i>American Heart Journal</i> , 1988 , 116, 206-7	4-9 15
83	New antiarrhythmic drugs. 1988 , 35, 286-319	23
82	Effect of oral cibenzoline on steady-state digoxin concentrations in healthy volunteers. 1988 , 28, 29-35	5
81	Amiodarone in the management of cardiac arrhythmias: current concepts. 1988 , 72, 321-58	17
80	Management of Arrhythmias in Heart Failure. 1989 , 7, 145-169	14
79	Combined anti-arrhythmic therapy with class 1 and class 3 drugs. 1989 , 65, 519-24	5
78	A general overview of amiodarone toxicity: its prevention, detection, and management. 1989 , 31, 393-426	91
77	The efficacy of amiodarone in the treatment of ventricular tachycardia or ventricular fibrillation. 1989 , 31, 319-54	29
76	The digoxin-amiodarone interaction. 1989 , 3, 25-8	34
75	Effect of amiodarone on the disposition of acetaminophen in the rat. 1989 , 78, 900-2	1
74	Pharmacokinetic drug interactions with amiodarone. 1989 , 17, 130-40	36

73	Adverse effects of amiodarone. Pathogenesis, incidence and management. 1989 , 4, 246-53		25
72	Methotrexate induced skin necrosis: a drug interaction with amiodarone?. 1989 , 299, 980-1		7
71	Selecting appropriate first-line antiarrhythmic agents: comparative pharmacological profiles. 1990 , 13, 1488-500		1
70	Cytotoxic interactions of cardioactive cationic amphiphilic compounds in primary rat hepatocytes in culture. 1990 , 12, 48-58		12
69	Risk-benefit assessment of amiodarone in the treatment of cardiac arrhythmias. 1990 , 5, 286-304		12
68	Long-term follow-up of amiodarone therapy in the young: continued efficacy, unimpaired growth, moderate side effects. 1990 , 15, 1118-24		74
67	Practical aspects of the use of amiodarone. 1991 , 41 Suppl 2, 67-73		4
66	Side effects from amiodarone. <i>American Heart Journal</i> , 1991 , 121, 158-71	4.9	110
65	The use of associated propafenone in patients with amiodarone-resistant ventricular tachycardia. 1991 , 31, 187-97		1
64	Effect of glutathione depletion on the in vivo inhibition of drug metabolism by agents forming an inactive cytochrome P-450 Fe(II):metabolite complex. Studies with amiodarone and troleandomycin. 1991 , 80, 225-8		5
63	Continuous spinal anaesthesia for abdominal surgery in a patient receiving amiodarone. 1991 , 38, 341-4		3
62	Advances in antiarrhythmic drug therapy. 1992 , 23, 179-225		1
61	Interactions with cardiovascular drugs. 1993 , 18, 531-81		3
60	Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery. 1993 , 72, 423-7		45
59	Amiodarone-induced thyrotoxicosis: is there a place for surgery?. 1993 , 17, 622-6; discussion 627		32
58	A consensus report on antiarrhythmic drug use. 1994 , 17, 103-16		31
57	Sudden hypothyroidism and amiodarone-lithium combination: an interaction. 1995 , 9, 827-8		1
56	Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA). <i>American Heart Journal</i> , 1995 , 130, 494-500	4.9	63

55	Calcium antagonists. Drug interactions of clinical significance. 1995 , 13, 157-87	19
54	Effects of amiodarone on thyroid function. 1997 , 126, 63-73	188
53	Intravenous amiodarone. 1997 , 29, 1190-8	87
52	Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs. 1997 , 80, 16G-23G	28
51	Adverse effects of amiodarone. 1998 , 21, 108-20	53
50	Adverse cardiovascular drug interactions. 2000 , 25, 621-76	9
49	Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. 2000 , 160, 1741-8	131
48	Classification and pharmacology of antiarrhythmic drugs. <i>American Heart Journal</i> , 2000 , 140, 12-20	4-9 35
47	Antiarrhythmic agents: drug interactions of clinical significance. 2000 , 23, 509-32	72
46	Anaesthesia for amiodarone-induced thyrotoxicosis: a case review. 2001 , 29, 24-9	12
45	Amiodaron. 2001 , 38, 169-178	9
44	Surgical considerations for treatment of amiodarone-induced thyrotoxicosis. 2001 , 58, 478-80	1
43	Lack of interaction between amiodarone and mexiletine in cardiac arrhythmia patients. 2002 , 42, 342-6	6
42	Use of cardiovascular medications in the elderly. 2002 , 85, 203-15	32
41	The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. 2002 , 11, 569-76	40
40	Pharmacological cardioversion of recent onset atrial fibrillation with intravenous amiodarone in patients receiving long-term amiodarone therapy: is it reasonable?. 2003 , 8, 19-26	8
39	Potentially significant drug interactions of class III antiarrhythmic drugs. 2003 , 26, 421-38	66
38	Phenylacetylglucine, a putative biomarker of phospholipidosis: its origins and relevance to phospholipid accumulation using amiodarone treated rats as a model. 2004 , 9, 271-90	76

37	Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol. 2005 , 20, 423-7		12
36	Pharmacokinetic characteristics of amiodarone in long-term oral therapy in Japanese population. 2005 , 28, 1934-8		18
35	Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. 2006 , 21, 501-5		21
34	The effect of levosimendan during long-term amiodarone treatment in dogs. 2006 , 99, 27-32		1
33	Anaesthesia for caesarean section in a patient receiving high dose amiodarone for fetal supraventricular tachycardia. 1994 , 49, 406-8		3
32	Fetal tachycardia: a role for amiodarone as first- or second-line therapy?. 2008 , 101, 619-27		23
31	Toxicity in Doberman Pinchers with ventricular arrhythmias treated with amiodarone (1996-2005). 2009 , 23, 1-6		18
30	Updates on cytochrome P450-mediated cardiovascular drug interactions. 2009 , 16, 155-63		11
29	Pharmacologic Interactions in the CICU. 2010 , 516-531		1
28	Updates on cytochrome p450-mediated cardiovascular drug interactions. 2010 , 56, 163-79		9
27	Agreement among four drug information sources for the occurrence of warfarin drug interactions in Brazilian heart disease patients with a high prevalence of <i>Trypanosoma cruzi</i> infection. 2013 , 69, 919-28		1
26	Clinical Pharmacology of Antiarrhythmic Drugs. 2013 , 343-364		2
25	Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels. <i>Pharmacogenomics</i> , 2013 , 14, 215-23	2.6	28
24	Risk Factors for Traumatic Brain Injuries During Falls in Older Persons. <i>Journal of Head Trauma Rehabilitation</i> , 2015 , 30, E9-17	3	21
23	The role of CYP 3A4 and 1A1 in amiodarone-induced hepatocellular toxicity. <i>Toxicology Letters</i> , 2016 , 253, 55-62	4.4	29
22	Interaction between amiodarone and hepatitis-C virus nucleotide inhibitors in human induced pluripotent stem cell-derived cardiomyocytes and HEK-293 Cav1.2 over-expressing cells. <i>Toxicology and Applied Pharmacology</i> , 2016 , 308, 66-76	4.6	13
21	Drug Metabolism in Cardiovascular Disease. 2017 , 139-156		
20	Guidelines for Therapeutic Drug Monitoring of Cardiovascular Drugs Clinical Use of Blood Drug Concentration Monitoring (JCS 2015) - Digest Version. <i>Circulation Journal</i> , 2017 , 81, 581-612	2.9	19

19	Efficacy and Safety Outcomes of Direct Oral Anticoagulants and Amiodarone in Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2018 , 131, 573.e1-573.e8	2.4	13
18	Pharmacologic Interactions. 2019 , 432-445.e7		
17	Amiodarone and thyroid physiology, pathophysiology, diagnosis and management. <i>Trends in Cardiovascular Medicine</i> , 2019 , 29, 285-295	6.9	23
16	Clinical Pharmacology of Antiarrhythmic Drugs. 2007 , 433-446		1
15	Propafenone for cardiac arrhythmias. <i>American Journal of the Medical Sciences</i> , 1992 , 303, 123-8	2.2	5
14	Adverse Drug Reactions and Drug-Drug Interactions. 2006 , 1678-1703		
13	Successful use of nifekalant hydrochloride for 37 days in a patient with refractory ventricular tachycardia following septic shock. <i>Journal of the Japanese Society of Intensive Care Medicine</i> , 2007 , 14, 345-346	0	1
12	Status of Class III Antiarrhythmic Drugs: Amiodarone, Bretylium and Sotalol. <i>Developments in Cardiovascular Medicine</i> , 1985 , 143-166		
11	Therapie der Erregungsbildungs- und -leitungsstörungen. 1989 , 660-703		
10	The oral antiarrhythmic drugs. <i>Progress in Drug Research Fortschritte Der Arzneimittelforschung Progres Des Recherches Pharmaceutiques</i> , 1990 , 35, 151-247		2
9	Medikamentöse Intervention bei Herzrhythmusstörungen. 1995 , 303-346		
8	Herzchirurgie. 1995 , 605-667		
7	Therapie der Erregungsbildungs- und Leitungsstörungen. 1996 , 1214-1277		
6	Pharmacodynamic drug-drug interactions in the intensive care unit: Single-center experience and literature review. <i>Annales Academiae Medicae Silesiensis</i> , 2018 , 72, 53-61	0.1	
5	Newer Cardiac Agents: Antiarrhythmics and Antianginal Agents. <i>Clinics in Laboratory Medicine</i> , 1987 , 7, 567-585	2.1	
4	Unilateral subarachnoid block for ankle arthrodesis in patient on long term amiodarone therapy. <i>Journal of Anaesthesiology Clinical Pharmacology</i> , 2010 , 26, 566	1.3	
3	Antiarrhythmic agents and torsades de pointes. 2022 , 183-211		
2	New antiarrhythmic drugs in pediatric use: amiodarone. <i>Pediatric Cardiology</i> , 1994 , 15, 132-8	2.1	11

- 1 Pharmacokinetic and Pharmacodynamic Consequences of Metabolism-Based Drug Interactions with Alprazolam, Midazolam, and Triazolam. **1999**, 39, 1109-1125